Chiesi Group

Chiesi Ventures is the investment arm of Chiesi Group, a research-oriented international biopharmaceutical group founded in 1935 and headquartered in Parma, Italy. The venture vehicle invests in early-stage therapies and technologies for rare diseases, an area that corresponds with one of the parent group's four core therapeutic fields, alongside respiratory health, neonatology and special care. The group's rare disease pipeline spans lysosomal storage diseases, rare hematology, ophthalmology disorders and rare immunodeficiencies, providing domain context for the areas in which the ventures team evaluates external opportunities.

The parent company ranks among the top 50 pharmaceutical companies globally, with more than 8,000 employees across 31 countries, global sales exceeding €3 billion and year-over-year growth of 10%. It opened a Biotech Center of Excellence research and manufacturing facility in 2024. Specific fund size, check size and stage parameters for Chiesi Ventures are not disclosed in the information provided.

Chiesi Group is family-owned, now in its third generation, and operates as a Benefit Corporation with sustainability written into its bylaws; it has been a certified B Corp since 2019 and describes itself as the world's largest pharmaceutical group to hold that certification. Its stated research orientation is anchored to a patient-focused principle of 'no patient left behind', with formal commitment to measuring impact on patients, the planet and communities.